WellPatch Vapor Pads recalled
This article was originally published in The Tan Sheet
Executive Summary
FDA and Metholatum have issued a voluntary recall for WellPatch Cough & Cold Soothing Vapor Pads due to the possibility of pediatric ingestion. The topical cough suppressant label indicates the product is suitable for children 2 years and older. The placement of the products on the chest gives young children easy access to remove the patches from their chests and possibly ingest them. Adverse events associated with menthol ingestion range from minor symptoms to seizures, an FDA MedWatch release notes. No serious adverse events linked to the WellPatch product have been reported to date. Triaminic Vapor Patches were similarly recalled in June 2006 due to reported adverse events related to pediatric ingestion (1"The Tan Sheet" June 26, 2006, p. 8)...
You may also be interested in...
Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis
Eight complaints of adverse health effects resulting from accidental ingestion of the Triaminic Vapor Patch have prompted a nationwide recall of products in the line by Novartis Consumer Healthcare
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.